CN107836558A - A kind of antitumor haematococcus pressed candy of reducing pressure and sugar anti-trioxypurine and application - Google Patents
A kind of antitumor haematococcus pressed candy of reducing pressure and sugar anti-trioxypurine and application Download PDFInfo
- Publication number
- CN107836558A CN107836558A CN201711290914.6A CN201711290914A CN107836558A CN 107836558 A CN107836558 A CN 107836558A CN 201711290914 A CN201711290914 A CN 201711290914A CN 107836558 A CN107836558 A CN 107836558A
- Authority
- CN
- China
- Prior art keywords
- haematococcus
- pressed candy
- parts
- weight ratio
- acer truncatum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000168525 Haematococcus Species 0.000 title claims abstract description 39
- 235000009508 confectionery Nutrition 0.000 title claims abstract description 34
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 19
- 241000219226 Acer truncatum Species 0.000 claims abstract description 26
- 241000168517 Haematococcus lacustris Species 0.000 claims abstract description 22
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 19
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 15
- 201000001421 hyperglycemia Diseases 0.000 claims abstract description 10
- 201000005569 Gout Diseases 0.000 claims abstract description 9
- 230000002526 effect on cardiovascular system Effects 0.000 claims abstract description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 7
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims abstract description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 7
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 6
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims description 5
- 241000195493 Cryptophyta Species 0.000 claims description 2
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 abstract description 14
- 235000013793 astaxanthin Nutrition 0.000 abstract description 14
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 abstract description 14
- 229940022405 astaxanthin Drugs 0.000 abstract description 14
- 239000001168 astaxanthin Substances 0.000 abstract description 14
- 238000000034 method Methods 0.000 abstract description 9
- 238000004519 manufacturing process Methods 0.000 abstract description 8
- 239000000203 mixture Substances 0.000 abstract description 3
- 206010020772 Hypertension Diseases 0.000 abstract description 2
- 238000009472 formulation Methods 0.000 abstract description 2
- 230000005802 health problem Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 229930195730 Aflatoxin Natural products 0.000 description 2
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 208000008469 Peptic Ulcer Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 239000005409 aflatoxin Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000010893 paper waste Substances 0.000 description 2
- 208000011906 peptic ulcer disease Diseases 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241001262079 Cutleriales Species 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- -1 Flavone compound Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 208000020717 oral cavity carcinoma Diseases 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Botany (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a kind of antitumor haematococcus pressed candy of reducing pressure and sugar anti-trioxypurine and application, the haematococcus pressed candy, include according to the raw material of mass percent：1 10 parts of chitosan oligosaccharide, 3 10 parts of microcrystalline cellulose, 28 parts of sodium cellulose glycolate, acer truncatum seed oily 0.5 1 parts, 50 80 parts of haematococcus pluvialis.The weight ratio of the haematococcus pluvialis and acer truncatum seed oil is 90 110：1, gout, hyperglycaemia, cardiovascular and cerebrovascular diseases, preferred weight ratio 100 can be treated：1.The weight ratio of the haematococcus pluvialis and acer truncatum seed oil is 40 60：1, can be antitumor, preferred weight ratio 50：1.The astaxanthin remained in haematococcus pluvialis of high degree of the present invention, the strict content astaxanthin controlled in haematococcus pressed candy is 6 milligrams, so that haematococcus pressed candy production efficiency is higher, alleviates the health problem of hypertension, hyperglycaemia and tumour patient, substantially reduce treatment cost.Inventive formulation is easily grasped, and technique is simple to operation.
Description
Technical field
The present invention relates to confectionery art, the antitumor haematococcus pressed candy of specifically a kind of reducing pressure and sugar anti-trioxypurine
And application.
Background technology
Haematococcus pluvialis are called lake life haematococcus or lake green blood ball algae again, are a kind of green algas of generally existing, belong to group
Cutleriales, haematococcus section.There is no any virose report in the document related to haematococcus.Currently, haematococcus pluvialis are public
Think the best biology of production natural astaxanthin in nature, therefore, astaxanthin is extracted undoubtedly with wide using this microalgae
Development prospect, it has also become in recent years in the world natural astaxanthin production study hotspot.Astaxanthin is that generally acknowledged forth generation resists
Oxidant, and the most strong antioxidant of nature that the mankind have found so far, antioxidation activity, the ability for removing free radical
It it is 1100 times, 50 times of Co-Q10 of vitamin E considerably beyond existing any product.
Astaxanthin can significantly inhibit the canceration at initial stage of chemicals induction, have to the epithelial cell in carcinogen
The effect of antiproliferative effect and reinforced immunological function, such as suppress the growth of carcinoma of urinary bladder, carcinoma of mouth, colon cancer, stomach cancer and breast cancer.
Astaxanthin can also reduce the carcinogenicity of aflatoxin, the quantity and volume of the tumor cell of liver to reducing aflatoxin induction
Work well.Proved by decades clinical practice, natural astaxanthin have it is anti-oxidant, protection skin and eyes, resistance radiation,
The effect such as anti-aging, antitumor, anti-inflammatory, antifatigue, prevention cardiovascular and cerebrovascular disease, to enhancing human immune system and delays
Aging is all significant, and " healthy soft gold ", " edible diamond " are described as by life scholar.
Acer truncatum seed oil, is a kind of new resource food, is process by the seed of the endemic tree acer truncatum of China
Vegetable fat.Flavone compound is the active drug of anticancer.Acer truncatum bunge flavone and acer truncatum buge oil, the oil have regulation immunity
Function.The occurrence and development of tumour and body immunity have very big relation.The immune system disorder of most tumor patients, its
Immunocyte can not remove spontaneous cancer cell in vivo, cancer cell is hidden in vivo for a long time, have no limiting growth, and the oil can be with
NK cytoactives are improved, the double action of Cellular Immunity and humoral immunity is improved and strengthens immunity of organisms.The aging of people
The process exactly aoxidized, therefore, taking some oxidation resistant materials can be to reach the purpose of anti-aging.At present, food work
In industry, cosmetic industry is the antioxidant of chemical synthesis mostly.Scientist has filtered out more than 100 kinds of natural plants and resisted
Oxidation control tests, and as a result shows that the antioxidation activity of acer truncatum bunge flavone is best.
But utilization of the prior art to above-mentioned raw materials is unreasonable, content astaxanthin is not high, and haematococcus raw material availability is low,
A kind of biological products that can suppress growth of cancer cells can not be provided for cancer patient.
The content of the invention
It is an object of the invention to provide a kind of antitumor haematococcus pressed candy of reducing pressure and sugar anti-trioxypurine and application, with
Solve the problems, such as to propose in above-mentioned background technology.
To achieve the above object, the present invention provides following technical scheme：
A kind of antitumor haematococcus pressed candy of reducing pressure and sugar anti-trioxypurine, includes according to the raw material of mass percent：Chitosan oligosaccharide
1-10 parts, microcrystalline cellulose 3-10 parts, sodium cellulose glycolate 2-8 parts, acer truncatum seed oil 0.5-1 parts, haematococcus pluvialis 50-80
Part.
As the further scheme of the present invention：The weight ratio of haematococcus pluvialis and acer truncatum seed oil is 40-110：1.
As the further scheme of the present invention：The weight ratio of haematococcus pluvialis and acer truncatum seed oil is 50-100：1.
Another object of the present invention is to provide the haematococcus pressed candy and is preparing treatment gout, hyperglycaemia, cardiovascular and cerebrovascular
Application in medicine.
As the further scheme of the present invention：The weight ratio of the haematococcus pluvialis and acer truncatum seed oil is 90-110：1,
Gout, hyperglycaemia, cardiovascular and cerebrovascular diseases can be treated.
As the further scheme of the present invention：The weight ratio of the haematococcus pluvialis and acer truncatum seed oil is 100：1, can
Treat gout, hyperglycaemia, cardiovascular and cerebrovascular diseases.
Application of the haematococcus pressed candy in tumor is prepared.
As the further scheme of the present invention：The weight ratio of the haematococcus pluvialis and acer truncatum seed oil is 40-60：1, energy
It is enough antitumor.
As the further scheme of the present invention：The weight ratio of the haematococcus pluvialis and acer truncatum seed oil is 50：1, can
It is antitumor.
Compared with prior art, the beneficial effects of the invention are as follows：
The astaxanthin remained in haematococcus pluvialis of high degree of the present invention, the strict shrimp controlled in haematococcus pressed candy are blue or green
Cellulose content is 6 milligrams so that haematococcus pressed candy production efficiency is higher, and a kind of haematococcus piece of tablet is provided for domestic market
The use of terminal, reduce consumer cost of the tumor patient to astaxanthin；Domestic market is put into the form of tablet, is dropped significantly
The low domestic consumer cost to astaxanthin, alleviate the health problem of hypertension, hyperglycaemia and tumour patient, substantially reduce patient's
Treatment cost, a kind of quality-high and inexpensive anti-tumor agent is provided for tumor patient.The present invention also improves the storage time of candy, greatly
The big finished product efficiency and quality for improving pressed candy, reduces the waste rate of resource, has saved production cost.Inventive formulation
Easily grasp, technique is simple to operation, and a kind of end product of haematococcus is provided for consumer, has important dissemination.
Embodiment
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described,
Obviously, described embodiment is only part of the embodiment of the present invention, rather than whole embodiments.Based in the present invention
Embodiment, the every other embodiment that those of ordinary skill in the art are obtained under the premise of creative work is not made, all
Belong to the scope of protection of the invention.
Embodiment 1 is hypoglycemic, anti-trioxypurine
In the embodiment of the present invention, the antitumor haematococcus pressed candy of a kind of reducing pressure and sugar anti-trioxypurine, according to mass percent
Raw material includes：10 parts of chitosan oligosaccharide, 50 parts of haematococcus pluvialis, 3 parts of microcrystalline cellulose, 8 parts of sodium cellulose glycolate and acer truncatum seed
0.5 part of oil.
Make：Raw material is poured into three-dimensional mixer and stirred, places 24 hours and bottles, seal, labelling, stamp, vanning
Storage.The haematococcus pressed candy is specifically to be made using following preparation method：
（1）Antenatal preparation, close inspection is carried out to production machine, metrical instrument, working environment and sanitary condition, and confirm its symbol
Close production requirement；
（2）Dispensing is weighed, gets raw material according to production ordering, and weigh accurately；
（3）Mixed powder, it will weigh in accurate supplementary material input three-dimensional mixer and mix 15min, and inspection by sampling, qualified entrance
Next procedure；
（4）Tabletting, sheeting operation, and inspection by sampling plain piece are carried out to mixed raw material by tablet press machine, it is qualified to enter lower road
Process；
（5）Piece is coated and picked up to plain piece, is selected qualified coating tablet and is carried out next procedure, it is waste paper to select underproof,
Waste paper abandons it；
（6）Metal detection inspection, by qualified coating tablet, load the PE bags of 20kg/ bags, by metal detector, it is without exception enter
Enter next procedure, exception occur needs to exclude；
（7）Packing, coating tablet is packed using Aluminum-plastic composite bag, and often packed amount be no more than 15kg, and examine it is qualified enter
Enter next procedure；
（8）Storage, packaged middle product coating tablet is handled into storage formality, every 60 a bottlings, sealing after the assay was approved
Labelling, stamp vanning storage.
Curative effect：Edible for patients haematococcus pressed candy more than two months, blood glucose drops to 4.5mmol/L by original 5.8mmol/L.
Uric acid (gout) drops to 450 μm of ol/L by 800 μm of original ol/L.
Embodiment 2 treats gout, hyperglycaemia, cardiovascular and cerebrovascular diseases
In the embodiment of the present invention, the antitumor haematococcus pressed candy of a kind of reducing pressure and sugar anti-trioxypurine, according to mass percent
Raw material includes：1 part of chitosan oligosaccharide, 80 parts of haematococcus pluvialis, 6.1 parts of microcrystalline cellulose, 2 parts of sodium cellulose glycolate and acer truncatum seed
0.8 part of oil.
Preparation method：Raw material is poured into three-dimensional mixer and stirred, places 24 hours and bottles, seal, labelling, stamp,
Vanning storage.Specific preparation technology is same as Example 1.
Curative effect：Patient suffers from angiocardiopathy more than 20 years and has heart infarction, and 200 meters are walked just before not eating haematococcus pressed candy
There is syndrome characterized by dyspnea, uncomfortable in chest；Edible astaxanthin eats oil capsule 6 months, and daily walking does not occur syndrome characterized by dyspnea, uncomfortable in chest more than 6000 meters
And weak sense.B ultrasound and blood test prompting indices are normal.
Embodiment 3 is antitumor, extends life-span and the quality of life of tumour patient
In the embodiment of the present invention, the antitumor haematococcus pressed candy of a kind of reducing pressure and sugar anti-trioxypurine, according to mass percent
Raw material includes：2 parts of chitosan oligosaccharide, 50 parts of haematococcus pluvialis, 3 parts of microcrystalline cellulose, 5 parts of sodium cellulose glycolate and acer truncatum seed oil
1 part.
Make tabletting：Raw material is poured into three-dimensional mixer and stirred, places 24 hours and bottles, seal, labelling, stamp,
Vanning storage.Specific preparation technology is same as Example 1.
Curative effect：Patients w ith peptic ulcer disease, ulcer breaking-out is in great pain, and doctor suggests operative treatment.Take haematococcus pressed candy
Daily 24mg to 30mg, pain is disappeared substantially after one month, and the observation state of an illness is not reaccessed stomachache.
Embodiment 4 is antitumor, extends life-span and the quality of life of tumour patient
In the embodiment of the present invention, the antitumor haematococcus pressed candy of a kind of reducing pressure and sugar anti-trioxypurine, according to mass percent
Raw material includes：1.3 parts of chitosan oligosaccharide, 50 parts of haematococcus pluvialis, 10 parts of microcrystalline cellulose, 2 parts of sodium cellulose glycolate and acer truncatum
1 part of seed oil.
Make tabletting：Raw material is poured into three-dimensional mixer and stirred, places 24 hours and bottles, seal, labelling, stamp,
Vanning storage.Specific preparation technology is same as Example 1.
Curative effect：Patients w ith peptic ulcer disease, ulcer breaking-out is in great pain, and doctor suggests operative treatment.Take haematococcus pressed candy
Daily 24mg to 30mg, pain is disappeared substantially after one month, and the observation state of an illness is not reaccessed stomachache.
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, Er Qie
In the case of without departing substantially from spirit or essential attributes of the invention, the present invention can be realized in other specific forms.Therefore, no matter
From the point of view of which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the present invention is by appended power
Profit requires rather than described above limits, it is intended that all in the implication and scope of the equivalency of claim by falling
Change is included in the present invention.
Moreover, it will be appreciated that although the present specification is described in terms of embodiments, not each embodiment is only wrapped
Containing an independent technical scheme, this narrating mode of specification is only that those skilled in the art should for clarity
Using specification as an entirety, the technical solutions in the various embodiments may also be suitably combined, forms those skilled in the art
It is appreciated that other embodiment.
Claims (9)
1. the antitumor haematococcus pressed candy of a kind of reducing pressure and sugar anti-trioxypurine, it is characterised in that according to the raw material bag of mass parts
Include：Chitosan oligosaccharide 1-10 parts, microcrystalline cellulose 3-10 parts, sodium cellulose glycolate 2-8 parts, acer truncatum seed oil 0.5-1 parts, rain life are red
Ball algae 50-80 parts.
2. the antitumor haematococcus pressed candy of reducing pressure and sugar anti-trioxypurine according to claim 1, it is characterised in that rain is given birth to
The weight ratio of haematococcus and acer truncatum seed oil is 40-110：1.
3. the antitumor haematococcus pressed candy of reducing pressure and sugar anti-trioxypurine according to claim 1, it is characterised in that rain is given birth to
The weight ratio of haematococcus and acer truncatum seed oil is 50-100：1.
4. the haematococcus pressed candy as described in claim 1-3 is any is preparing treatment gout, hyperglycaemia, cardiovascular and cerebrovascular diseases medicine
Application in thing.
5. haematococcus pressed candy according to claim 4 is in treatment gout, hyperglycaemia, cardiovascular and cerebrovascular medicine is prepared
Application, it is characterised in that the weight ratio of the haematococcus pluvialis and acer truncatum seed oil is 90-110：1.
6. haematococcus pressed candy according to claim 5 is in treatment gout, hyperglycaemia, cardiovascular and cerebrovascular medicine is prepared
Application, it is characterised in that the weight ratio of the haematococcus pluvialis and acer truncatum seed oil is 100：1.
7. application of the haematococcus pressed candy in tumor is prepared as described in claim 1-3 is any.
8. application of the haematococcus pressed candy according to claim 7 in tumor is prepared, it is characterised in that
The weight ratio of the haematococcus pluvialis and acer truncatum seed oil is 40-60：1.
9. application of the haematococcus pressed candy according to claim 7 in tumor is prepared, it is characterised in that
The weight ratio of the haematococcus pluvialis and acer truncatum seed oil is 50：1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711290914.6A CN107836558A (en) | 2017-12-08 | 2017-12-08 | A kind of antitumor haematococcus pressed candy of reducing pressure and sugar anti-trioxypurine and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711290914.6A CN107836558A (en) | 2017-12-08 | 2017-12-08 | A kind of antitumor haematococcus pressed candy of reducing pressure and sugar anti-trioxypurine and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107836558A true CN107836558A (en) | 2018-03-27 |
Family
ID=61664790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711290914.6A Pending CN107836558A (en) | 2017-12-08 | 2017-12-08 | A kind of antitumor haematococcus pressed candy of reducing pressure and sugar anti-trioxypurine and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107836558A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111480836A (en) * | 2020-05-19 | 2020-08-04 | 昆明白鸥微藻技术有限公司 | Haematococcus pluvialis wall-broken algae tablet |
| WO2020178821A1 (en) * | 2019-03-03 | 2020-09-10 | Algatechnologies Ltd. | Compositions comprising algae powder and uses thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103504301A (en) * | 2013-09-30 | 2014-01-15 | 李树森 | Formulation and preparation method of astaxanthin oil with effects of reducing blood pressure, blood sugar and uric acid and preventing tumors |
| US20140314845A1 (en) * | 2013-04-19 | 2014-10-23 | Microfoods Japan, Co., Ltd. | Spherical erythritol granules for direct compression and process of producing same, process of producing tablets by tableting the erythritol granules with a pharmaceutically effective ingredient or nutritional ingredient, and tablets or ordinary candy tablets obtained thereby |
| CN106213505A (en) * | 2016-07-09 | 2016-12-14 | 威海百合生物技术股份有限公司 | A kind of Moringa Haematocoocus Pluvialls tabletting health product and preparation method thereof |
| CN106689618A (en) * | 2016-11-21 | 2017-05-24 | 云南爱尔康生物技术有限公司 | Astaxanthin tabletting candy preparation method |
| CN107259046A (en) * | 2017-06-07 | 2017-10-20 | 陕西必康制药集团控股有限公司 | Haematococcus pluvialis pressed candy with anti-oxidation function and preparation method thereof |
| CN107410643A (en) * | 2017-06-07 | 2017-12-01 | 陕西必康制药集团控股有限公司 | With haematococcus pluvialis pressed candy for alleviating visual fatigue and preparation method thereof |
-
2017
- 2017-12-08 CN CN201711290914.6A patent/CN107836558A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140314845A1 (en) * | 2013-04-19 | 2014-10-23 | Microfoods Japan, Co., Ltd. | Spherical erythritol granules for direct compression and process of producing same, process of producing tablets by tableting the erythritol granules with a pharmaceutically effective ingredient or nutritional ingredient, and tablets or ordinary candy tablets obtained thereby |
| CN103504301A (en) * | 2013-09-30 | 2014-01-15 | 李树森 | Formulation and preparation method of astaxanthin oil with effects of reducing blood pressure, blood sugar and uric acid and preventing tumors |
| CN106213505A (en) * | 2016-07-09 | 2016-12-14 | 威海百合生物技术股份有限公司 | A kind of Moringa Haematocoocus Pluvialls tabletting health product and preparation method thereof |
| CN106689618A (en) * | 2016-11-21 | 2017-05-24 | 云南爱尔康生物技术有限公司 | Astaxanthin tabletting candy preparation method |
| CN107259046A (en) * | 2017-06-07 | 2017-10-20 | 陕西必康制药集团控股有限公司 | Haematococcus pluvialis pressed candy with anti-oxidation function and preparation method thereof |
| CN107410643A (en) * | 2017-06-07 | 2017-12-01 | 陕西必康制药集团控股有限公司 | With haematococcus pluvialis pressed candy for alleviating visual fatigue and preparation method thereof |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020178821A1 (en) * | 2019-03-03 | 2020-09-10 | Algatechnologies Ltd. | Compositions comprising algae powder and uses thereof |
| CN111480836A (en) * | 2020-05-19 | 2020-08-04 | 昆明白鸥微藻技术有限公司 | Haematococcus pluvialis wall-broken algae tablet |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104257887B (en) | A kind of composition for promoting lead discharging and its application | |
| CN102813114A (en) | Gastrointestinal health preserving pulp and preparation method of gastrointestinal health preserving pulp | |
| CN102687823A (en) | Nutrition powder for resisting disease and strengthening body | |
| CN103783614A (en) | Astaxanthin apple vinegar beverage and fabrication method thereof | |
| CN107281032A (en) | A kind of composition of whitening spot-removing and preparation method thereof | |
| CN107836558A (en) | A kind of antitumor haematococcus pressed candy of reducing pressure and sugar anti-trioxypurine and application | |
| CN100998411A (en) | Health-care food with anti-oxidation and lowering weight functions | |
| CN107048365B (en) | A kind of citrus guarana product for being used for weight-reducing and its preparation method and application | |
| CN101336734B (en) | Instant alga food and processing method thereof | |
| CN100551267C (en) | Rich selenium zinc health food and preparation method thereof | |
| CN105663447A (en) | Slimming capsule and preparation method thereof | |
| CN102805303A (en) | Crude rehmannia root health-care noodles and preparation method thereof | |
| CN104957474A (en) | Moringa oleifera composition for reducing blood pressure and preparation method of moringa oleifera composition | |
| CN107125664A (en) | Treat constipation and reduce nutraceutical of body fat and preparation method thereof | |
| CN102440294A (en) | Water-soluble burdock residue dietary fiber milk powder candy | |
| CN106614903A (en) | Low-sugar nutritional bar and making method thereof | |
| CN101455256A (en) | Health-preserving tea | |
| CN105101817B (en) | Edible composition and preparation method thereof and the food comprising said composition | |
| CN105815712A (en) | Healthcare weight-losing konjac capsules and preparing method thereof | |
| CN105614861B (en) | Golden flower fibert chewable tablets and preparation method thereof | |
| CN102613576A (en) | Breast health and beauty nutritional tablets | |
| CN106962918A (en) | A kind of Multifunctional protective health granules and preparation method thereof | |
| CN107873933A (en) | A kind of preparation method of antitumor haematococcus pressed candy | |
| CN101584485A (en) | Haematococcus, smallanthus sonchifolius food | |
| CN104432093A (en) | Microalgae mulberry healthcare buccal tablet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180327 |